ルミラコキシブ
ルミラコキシブ 物理性質
- 融点 :
- 139-141°C
- 沸点 :
- 395.7±42.0 °C(Predicted)
- 比重(密度) :
- 1.363±0.06 g/cm3(Predicted)
- 貯蔵温度 :
- Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
- 溶解性:
- ≥29.4 mg/mL in DMSO; insoluble in H2O; ≥27.15 mg/mL in EtOH with ultrasonic
- 外見 :
- solid
- 酸解離定数(Pka):
- 4.18±0.10(Predicted)
- CAS データベース:
- 220991-20-8
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語 |
警告 |
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H302 |
飲み込むと有害 |
急性毒性、経口 |
4 |
警告 |
|
P264, P270, P301+P312, P330, P501 |
|
| 注意書き |
| P264 |
取扱い後は皮膚をよく洗うこと。 |
| P264 |
取扱い後は手や顔をよく洗うこと。 |
| P270 |
この製品を使用する時に、飲食または喫煙をしないこ と。 |
| P301+P312 |
飲み込んだ場合：気分が悪い時は医師に連絡する こと。 |
| P501 |
内容物/容器を．．．に廃棄すること。 |
|
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
SML2928 |
Lumiracoxib ≥98% (HPLC)
≥98% (HPLC) |
220991-20-8 |
10mg |
￥7140 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
SML2928 |
Lumiracoxib ≥98% (HPLC)
≥98% (HPLC) |
220991-20-8 |
50mg |
￥23400 |
2024-03-01 |
購入 |
ルミラコキシブ 化学特性,用途語,生産方法
効能
抗炎症薬, シクロオキシゲナーゼ2阻害薬
説明
As a second-generation, selective cyclooxygenase (COX-2) inhibitor, lumiracoxib
is devoid of the gastrointestinal issues that plague other non-selective, nonsteroidal,
anti-inflammatory drugs (NSAIDs) that crossover to COX-1. As an inhibitor
of the inducible COX-2 that is up-regulated in pathological processes of
pain and inflammation, lumiracoxib blocks the conversion of arachidonic acid to
prostaglandins, the mediators of the pathological effects. It’s mode of binding to
COX-2 has been found to differ from the other selective COX-2 inhibitors; the
carboxylic acid forms hydrogen bonds with Tyr-385 and Ser-530 in the catalytic site
rather than seeking interactions within the larger hydrophobic side pocket. Since lumiracoxib is mainly metabolized by CYP2C9, a study evaluating
the co-administration of lumiracoxib with fluconazole, a potent inhibitor of
CYP2C9, was conducted, and it concluded that there was no need for lumiracoxib
dose adjustment, since changes in the systemic exposure were not significant. No
serious adverse effects were reported, but in the small number of cases where
treatment was discontinued, Gastro intestinal (GI) and musculoskeletal complaints
were common.
化学的特性
Pale Yellow Solid
使用
Lumiracoxib is a selective cyclooxygenase-2-(COX-2) inhibitor and an anti-inflammatory agent (1,2,3,4).
定義
ChEBI: An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthrit
s, but was withdrawn due to concersns of hepatotoxicity.
ルミラコキシブ 上流と下流の製品情報
原材料
準備製品
ルミラコキシブ 生産企業
Global( 129)Suppliers
220991-20-8(ルミラコキシブ)キーワード:
- 220991-20-8
- 2-[2-[(2-chloro-6-fluoro-phenyl)amino]-5-methyl-phenyl]acetic acid
- 2-[(2-Chloro-6-fluorophenyl)amino]-5-methylbenzeneacetic Acid
- CGS 35189
- COX 189
- Prexige
- Lumaricoxib
- Benzeneacetic acid, 2-((2-chloro-6-fluorophenyl)amino)-5-methyl-
- Unii-V91T9204hu
- Lumiracoxib, COX-189, Prexige
- LuMiracoxib (COX-189)
- 2-(5-((2-chloro-6-fluorophenyl)amino)-2-methylphenyl)acetic acid
- 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid
- Lumiracoxib (CGS 35189
- 2-[2-(2-Chloro-6-fluorophenylamino)-5-methylphenyl]acetic ac...
- Prexige, Lumiracoxib
- Cyclooxygenase,Inhibitor,bone cancer,osteoarthritis,inflammatory,COX189,inhibit,hyperalgesic,COX 189,Lumiracoxib,COX,Metabolic Syndrome
- Xanthine Impurity 30
- ルミラコキシブ